Repaglinide, so far the only DREAM ligand tested in vivo for HD treatment, has a transient effect; in early disease stages, it effectively delays onset and slows progression of the symptoms, but in the long term does not prevent the fatal outcome of the disease. This evidence concerns the gene KCNIP3 and Huntington disease.